Physician profile
Curtis Rosebraugh
NPI 1104159391
$418,030.00
in general payments reported to CMS, 2019-2025
11 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $30K · 2021: $87K · 2022: $50K · 2023: $66K · 2024: $86K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $241K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $241,075.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $209,480.00 | 2020-2025 | Rinvoq, Armour Thyroid |
| Astrazeneca Pharmaceuticals Lp | $49,050.00 | 2023-2025 | |
| Hra Pharma | $36,587.50 | 2021-2022 | |
| Novo Nordisk INC | $26,000.00 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,000.00 | 2025 | |
| Merck Sharp & Dohme LLC | $22,125.00 | 2023-2025 | |
| Novo Nordisk As | $16,900.00 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $10,725.00 | 2019 | |
| Innocoll Pharmaceuticals Limited | $9,100.00 | 2021 | |
| Esperion Therapeutics, INC. | $6,562.50 | 2024-2025 | Nexlizet, Nexletol |
| Vertex Pharmaceuticals Incorporated | $6,500.00 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Rosebraugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.